Hanmi Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Hanmi Pharmaceuticals Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hanmi Pharmaceuticals Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hanmi Pharmaceuticals Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hanmi Pharmaceuticals Co Ltd (Hanmi Pharmaceuticals) develops prescription drugs and over-the-counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements, nutritional supplements, calcium supplements, vitamins, antiemetics in the form of tablets, capsules, injections, and syrup, among others. The products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis, and others. The company operates manufacturing facilities in Hwaseong, Songpa, and Pyeongtaek, South Korea. It supplies products and APIs in various countries in Europe, Asia-Pacific, and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
214, Muha-Ro, Paltan-Myeon, Hwaseong, Seoul, 18536
Website
www.hanmipharm.com
Telephone
82 313 505600
No of Employees
2,331
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
128940 (KRX)
Revenue (2024)
$1.1B
3.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.8%
(2024 vs 2023)
Market Cap*
$3.3B
Net Profit Margin (2024)
XYZ
35.1%
(2024 vs 2023)
* As of and is in US$
Hanmi Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Drugs: | Luminate |
| Antibiotics | Lapscovery |
| Antihistamines | Amosartan |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In June, the company acquired Aptose Biosciences Inc, a biotechnology company. |
| 2026 | New Products/Services | In June, the company launched HM500197, a muscle-building obesity treatment candidate. |
| 2026 | Contracts/Agreements | In May, the company entered into a supply agreement with Organon to export three combination medicines for the Malaysian and Philippine markets. |
Competitor Comparison
| Key Parameters | Hanmi Pharmaceuticals Co Ltd | Yuhan Corp | GC Biopharma Corp | Daewoong Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Yongin-si | Hwaseong | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 2,331 | 1,594 | 2,355 | 1,749 | 273 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Young-Sook Song | Chairwoman | Executive Board | - | - |
| Jae-Hyun Park | Chief Executive Officer; President | Senior Management | 2024 | 58 |
| Lim Jong-Yoon | President | Senior Management | - | 54 |
| Lim Jong-Hoon | President | Senior Management | - | 49 |
| Park Myung-hee | Executive Director | Senior Management | - | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer